Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna developed its vaccine in partnership ... how to mount a defensive reaction against an infection. The polio vaccine invented by Jonas Salk used this approach, and flu vaccines use this ...

“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

A team of Yale researchers recently published promising results from a clinical trial testing the effectiveness of a new ...

Moderna did not include potential sales for new products, including its next-generation Covid-19 vaccine, in its 2025 estimates. The team was asked whether this was a reflection of any uncertainty ...

Moderna (NASDAQ:MRNA) is targeting market approval of a personalized vaccine the company is developing with Merck (NYSE:MRK) ...